You are here:

MS in the media - 12 January 2018

Published on

6 - 12 January 2018

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

First PPMS drug licensed

Ocrevus (ocrelizumab) has been licensed by the EU as a treatment for active relapsing and early primary progressive MS.  This is the first drug to be licensed for primary progressive MS. Ocrevus will need to be assessed by NICE and SMC before it is available on the NHS

Source: Reuters

MS Trust link: Ocrevus (ocrelizumab)

Comparison of disease modifying drugs

Swedish research compared six disease modifying drugs for relapsing remitting MS - rituximab, Avonex, Rebif, Copaxone, Gilenya, Tecfidera and Tysabri. People who started on rituximab were less likely to stop or switch drugs. They also had fewer relapses or activity visible on MRI. The article discusses the shortcomings of this type of trial.  Rituximab is not available as an MS drug in the UK

Source: MedPage Today

MS Trust link: MS Decisions - a guide to the disease modifying drugs for relapsing remitting MS

Paralympic curler with MS

Hugh Nibloe has been named as part of the British curling team for this year's winter Paralympics in South Korea. He talks about how sport helped him cope with his diagnosis after a difficult start

Source: BBC

MS Trust link: Personal stories of life with MS

Bad living conditions for people with MS in Glasgow

An MS nurse has spoken out about a lack of suitable accommodation for people with MS in Glasgow

Source: Glasgow Evening Times

MS Trust link: Housing adaptations

Print this page